{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:02:58Z","timestamp":1788825778461,"version":"build-2803163510"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/md.0b013e3182380a76","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T04:58:03Z","timestamp":1319605083000},"page":"359-371","source":"Crossref","is-referenced-by-count":240,"title":["Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy"],"prefix":"10.1097","volume":"90","author":[{"given":"Roberto","family":"P\u00e9rez-Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ndido","family":"D\u00edaz-Lagares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garc\u00eda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Lopez-Roses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"P\u00e9rez-de-Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Retamozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Bov\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Maria","family":"Sanchez-Tapias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210226","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/art.21216","article-title":"Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab.","volume":"52","author":"Anelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R2-1-20210226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/RHU.0b013e318181b89d","article-title":"Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.","volume":"14","author":"Benucci","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R3-1-20210226","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3899\/jrheum.091107","article-title":"Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists.","volume":"37","author":"Bernatsky","year":"2010","journal-title":"J Rheumatol"},{"key":"R4-1-20210226","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R5-1-20210226","first-page":"421","article-title":"Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.","volume":"35","author":"Cansu","year":"2008","journal-title":"J Rheumatol"},{"key":"R6-1-20210226","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases.","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R7-1-20210226","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"R8-1-20210226","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R9-1-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1746.2009.06165.x","article-title":"Toward elimination and eradication of hepatitis B.","volume":"25","author":"Chen","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R10-1-20210226","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrgastro.2009.107","article-title":"Hepatitis B virus variants.","volume":"6","author":"Chotiyaputta","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R11-1-20210226","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.","volume":"36","author":"Chung","year":"2009","journal-title":"J Rheumatol"},{"key":"R12-1-20210226","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ibd.20216","article-title":"Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease.","volume":"13","author":"Colbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R13-1-20210226","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2008.09.057","article-title":"Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection.","volume":"60","author":"Conde-Taboada","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R14-1-20210226","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00054725-200409000-00035","article-title":"M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.","volume":"10","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R15-1-20210226","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.1840400418","article-title":"Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.","volume":"40","author":"Di Marco","year":"2004","journal-title":"Hepatology"},{"key":"R16-1-20210226","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"key":"R17-1-20210226","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"R18-1-20210226","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"R19-1-20210226","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0168-8278(89)90142-6","article-title":"Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.","volume":"9","author":"Fattovich","year":"1989","journal-title":"J Hepatol"},{"key":"R20-1-20210226","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-3083.2010.03754.x","article-title":"Safety of anti-tumour necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature.","volume":"25","author":"Fotiadou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"R21-1-20210226","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.","volume":"63","author":"Furst","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R23-1-20210226","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10096-008-0628-x","article-title":"Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.","volume":"28","author":"Garcia-Vidal","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R24-1-20210226","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","article-title":"Noncytolytic control of viral infections by the innate and adaptive immune response.","volume":"19","author":"Guidotti","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"R25-1-20210226","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"R26-1-20210226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1525-1373.2000.22335.x","article-title":"Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.","volume":"223","author":"Herbein","year":"2000","journal-title":"Proc Soc Exp Biol Med"},{"key":"R28-1-20210226","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1128\/JVI.77.4.2469-2476.2003","article-title":"Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes.","volume":"77","author":"Kasahara","year":"2003","journal-title":"J Virol"},{"key":"R29-1-20210226","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s10067-008-0896-y","article-title":"Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports.","volume":"27","author":"Kaur","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R30-1-20210226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor blockade and the risk of viral infection.","volume":"6","author":"Kim","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R31-1-20210226","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3899\/jrheum.090436","article-title":"Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.","volume":"37","author":"Kim","year":"2010","journal-title":"J Rheumatol"},{"key":"R34-1-20210226","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-009-1149-4","article-title":"Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.","volume":"28","author":"Li","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R36-1-20210226","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation.","volume":"13","author":"Madonia","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R37-1-20210226","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0016-5085(95)90694-0","article-title":"Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection.","volume":"108","author":"Marinos","year":"1995","journal-title":"Gastroenterology"},{"key":"R38-1-20210226","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1002\/cncr.25253","article-title":"Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.","volume":"116","author":"Matsue","year":"2010","journal-title":"Cancer"},{"key":"R39-1-20210226","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1478-3231.2010.02238.x","article-title":"Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection.","volume":"30","author":"Matsumoto","year":"2010","journal-title":"Liver Int"},{"key":"R40-1-20210226","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease.","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"R41-1-20210226","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R42-1-20210226","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1478-3231.2007.01665.x","article-title":"Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.","volume":"28","author":"Montiel","year":"2008","journal-title":"Liver Int"},{"key":"R43-1-20210226","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach.","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R44-1-20210226","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00535-008-2165-x","article-title":"Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab.","volume":"43","author":"Ojiro","year":"2008","journal-title":"J Gastroenterol"},{"key":"R45-1-20210226","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"R46-1-20210226","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R47-1-20210226","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/rheumatology\/kem082","article-title":"Chronic viral hepatitis and TNF-alpha blockade.","volume":"46","author":"Raftery","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R48-1-20210226","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/rheumatology\/kep003","article-title":"Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection.","volume":"48","author":"Robinson","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R49-1-20210226","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R50-1-20210226","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10067-006-0392-1","article-title":"Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.","volume":"26","author":"Sakellariou","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R51-1-20210226","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1365-2249.1999.00812.x","article-title":"HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.","volume":"115","author":"Schlaak","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"R52-1-20210226","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/bmb\/ldp036","article-title":"The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease.","volume":"92","author":"Shale","year":"2009","journal-title":"Br Med Bull"},{"key":"R53-1-20210226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0168-8278(91)90945-8","article-title":"Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection.","volume":"12","author":"Sheron","year":"1991","journal-title":"J Hepatol"},{"key":"R54-1-20210226","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Furst DE; CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R55-1-20210226","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1006\/cyto.1996.0115","article-title":"Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases.","volume":"8","author":"Spengler","year":"1996","journal-title":"Cytokine"},{"key":"R56-1-20210226","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/acr.20209","article-title":"Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.","volume":"62","author":"Stine","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R57-1-20210226","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd2196","article-title":"Biologic therapies in rheumatology: lessons learned, future directions.","volume":"6","author":"Strand","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"R58-1-20210226","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1756-185X.2009.01393.x","article-title":"The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital sic.","volume":"12","author":"Suwannalai","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"R59-1-20210226","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/clinids\/18.2.194","article-title":"Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis.","volume":"18","author":"Torre","year":"1994","journal-title":"Clin Infect Dis"},{"key":"R60-1-20210226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10620-005-1295-8","article-title":"Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.","volume":"50","author":"Ueno","year":"2005","journal-title":"Dig Dis Sci"},{"key":"R62-1-20210226","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R63-1-20210226","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MEG.0b013e3283329d13","article-title":"Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.","volume":"22","author":"Verhelst","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R64-1-20210226","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard.2004.031187","article-title":"Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R65-1-20210226","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/323819a0","article-title":"Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.","volume":"323","author":"Wong","year":"1986","journal-title":"Nature"},{"key":"R66-1-20210226","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2165\/11319850-000000000-00000","article-title":"Predictors of treatment response in chronic hepatitis B.","volume":"69","author":"Wong","year":"2009","journal-title":"Drugs"},{"key":"R67-1-20210226","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/gut.2009.195834","article-title":"Managing HBV in patients with impaired immunity.","volume":"59","author":"Wursthorn","year":"2010","journal-title":"Gut"},{"key":"R69-1-20210226","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3899\/jrheum.081246","article-title":"Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.","volume":"36","author":"Zingarelli","year":"2009","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e3182380a76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:13Z","timestamp":1786047853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201111000-00001"}},"subtitle":["Analysis of 257 Cases"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e3182380a76","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}